Nevertheless, mutations in B2M, which stabilize intracellular peptides on the cell surface and play a vital role in antigen presentation, were demonstrated to be associated with acquired resistance to CTLA-4 and PD-1 inhibitors in melanoma (23). The gene discussed is CTLA4; the disease is melanoma.